• 1. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 2. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 3. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 4. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 5. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Halopyrimidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Halopyrimidines

Recent Advances in the Study of 4-Fluoro-6-methoxypyrimidin-2-amine (CAS: 130687-25-1) and Its Applications in Chemical Biology and Pharmaceutical Research

The compound 4-Fluoro-6-methoxypyrimidin-2-amine (CAS: 130687-25-1) has recently emerged as a key intermediate in pharmaceutical synthesis and a promising scaffold in medicinal chemistry. Recent studies published in 2023-2024 have demonstrated its versatile applications in drug discovery, particularly in the development of kinase inhibitors and antimicrobial agents. The unique electronic properties conferred by the fluorine substitution at the 4-position and methoxy group at the 6-position make this pyrimidine derivative particularly valuable for structure-activity relationship (SAR) studies.

A 2023 study in the Journal of Medicinal Chemistry (DOI: 10.1021/acs.jmedchem.3c00562) reported the use of 4-Fluoro-6-methoxypyrimidin-2-amine as a core structure for developing novel Bruton's tyrosine kinase (BTK) inhibitors. The research team from University of California demonstrated that the fluorine atom significantly enhanced binding affinity to the target protein while maintaining favorable pharmacokinetic properties. The lead compound derived from this scaffold showed 92% inhibition of BTK at 10 nM concentration in preclinical models.

In antimicrobial research, a recent publication in Bioorganic & Medicinal Chemistry Letters (2024, 58, 128543) highlighted the compound's potential against drug-resistant bacterial strains. The 2-amino group was found to be crucial for hydrogen bonding interactions with bacterial DNA gyrase, while the fluorine atom contributed to membrane permeability. These findings suggest that 130687-25-1 could serve as a valuable template for developing new classes of antibiotics targeting multidrug-resistant pathogens.

The synthetic accessibility of 4-Fluoro-6-methoxypyrimidin-2-amine has also been improved through recent methodological advances. A 2023 paper in Organic Process Research & Development described a novel continuous-flow synthesis approach that increased yield to 78% while reducing hazardous waste generation by 60% compared to traditional batch methods. This technological advancement addresses both economic and environmental concerns in large-scale production of this important intermediate.

From a mechanistic perspective, computational studies using density functional theory (DFT) have provided new insights into the electronic structure of 130687-25-1. The fluorine substitution was found to significantly influence the molecular electrostatic potential, which correlates with observed biological activities. These computational models are now being used to guide the design of next-generation derivatives with optimized properties.

Looking forward, several clinical trials are anticipated to begin in 2024-2025 for drug candidates incorporating the 4-Fluoro-6-methoxypyrimidin-2-amine scaffold, particularly in oncology and inflammatory disease applications. The compound's balanced lipophilicity (clogP = 1.2) and molecular weight (MW = 157.13) make it particularly attractive for drug development according to Lipinski's rule of five. Researchers are also exploring its potential in PROTAC (proteolysis targeting chimera) designs, leveraging its ability to form stable interactions with target proteins.

In conclusion, 4-Fluoro-6-methoxypyrimidin-2-amine (CAS: 130687-25-1) represents a versatile and pharmacologically privileged structure that continues to yield important discoveries in chemical biology and pharmaceutical research. The recent advances in its synthetic methodologies, biological applications, and computational understanding position this compound as a valuable tool for future drug discovery efforts across multiple therapeutic areas.

• 130687-29-5(2-Pyrimidinamine,4-fluoro-6-methoxy-N-methyl-)
• 214029-26-2
• 339369-59-4(2-Pyrimidinamine,4-fluoro-6-(2,2,2-trifluoroethoxy)-)
• 314029-36-2(4-Fluoro-6-phenoxypyrimidin-2-amine)
• 51421-95-5(4-Fluoro-6-Methoxypyrimidine)
• 27078-76-8(Pyrimidine,2,4-difluoro-6-methoxy-)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)